secwatch.observer — SEC 8-K summary
======================================

Issuer:     TriSalus Life Sciences, Inc. (TLSI)
CIK:        0001826667
Form:       8-K
Filed at:   2025-01-31T23:59:59+00:00
Accession:  0001826667-25-000011
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

TriSalus Life Sciences appoints two new directors, expands board to 11
----------------------------------------------------------------------

- William Valle (Class I, term to 2027) and Gary Gordon (Class III, term to 2026) appointed Jan 29, 2025.
- Valle receives $50k cash retainer plus $7.5k each for Audit and Compensation committees; initial option grant of 35k shares (3-yr vest).
- Gordon receives $50k cash retainer plus $7.5k for Science & Technology Committee; same option grant structure as Valle.
- No arrangements or understandings existed for selection of Valle or Gordon; no reportable transactions under Item 404(a).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1826667/000182666725000011/0001826667-25-000011-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1826667/000182666725000011/tlsi-20250129.htm
  HTML page:      https://secwatch.observer/filing/0001826667-25-000011

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer